Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Balaglitazone

🥰Excellent
Catalog No. TQ0272Cas No. 199113-98-9
Alias NN-2344, NN2344, NN 2344, DRF-2593, DRF2593, DRF 2593

Balaglitazone is a selective peroxisome proliferator-activated receptor (PPARγ) partial agonist with an EC50 value of 1.351 μM for human PPARγ.Balaglitazone can be used as a supplement to insulin therapy, regulates blood glucose, and can be used in studies of heart failure and myocardial infarction.

Balaglitazone

Balaglitazone

🥰Excellent
Purity: 99.74%
Catalog No. TQ0272Alias NN-2344, NN2344, NN 2344, DRF-2593, DRF2593, DRF 2593Cas No. 199113-98-9
Balaglitazone is a selective peroxisome proliferator-activated receptor (PPARγ) partial agonist with an EC50 value of 1.351 μM for human PPARγ.Balaglitazone can be used as a supplement to insulin therapy, regulates blood glucose, and can be used in studies of heart failure and myocardial infarction.
Pack SizePriceAvailabilityQuantity
1 mg78 €In Stock
Bulk & Custom
Add to Cart
Questions
View More
Select Batch
Purity:99.74%
Contact us for more batch information
Resource Download
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Product Introduction

Bioactivity
Description
Balaglitazone is a selective peroxisome proliferator-activated receptor (PPARγ) partial agonist with an EC50 value of 1.351 μM for human PPARγ.Balaglitazone can be used as a supplement to insulin therapy, regulates blood glucose, and can be used in studies of heart failure and myocardial infarction.
Targets&IC50
PPARγ (human):351 μM (EC50)
In vitro
Balaglitazone exhibits equal cytotoxicity in K562 and K562/DOX cells, with IC50 values of 0.117 μM and 0.53 μM, respectively, and reduces the cytotoxicity of doxorubicin in these cells[2].
In vivo
In male diet-induced obese rats, oral administration of Balaglitazone at 10 mg/kg suppresses overall blood glucose, reduces insulin levels, and increases body weight, with effects equivalent to 30 mg/kg pioglitazone[3].
Cell Research
MTT assay is used for cell viability analyses. Briefly, K562 and K562/DOX cells are seeded in a 96-well plate in RPMI-1640 medium supplemented with 10% FBS at the density of 2 × 104 cells/well. After 24 h incubation, various concentrations of doxorubicin (DOX) with or without balaglitazone are diluted in RPMI-1640 medium (without FBS) and added into each well. Experiments for each group are performed in triplicates and with a blank control. After 48 h of treatment, the medium is removed and 200 μL of RPMI-1640 medium supplemented with 10% FBS and 10% MTT (5 mg/mL) is added. After incubation for another 4 h, the reduced intracellular formazan product is dissolved by replacing 100 μL of RPMI-1640 medium with the same volume of dimethyl sulfoxide (DMSO). Absorbance values are measured at 570 nm with a microplate reader. The half-maximal inhibitory concentration (IC50) of each experiment is calculated. The resistance fold (RF) is calculated by dividing the IC50 value of treatment in resistant cells by the IC50 value of treatment in corresponding parental cells [2].
Animal Research
Antihyperglycaemic effects of balaglitazone and rosiglitazone are assessed in adult male diabetic db/db mice. At 14 weeks of age, animals are randomized according to fasting blood glucose into 11 groups (n = 6). Mice are dosed orally once daily for 9 days with vehicle (0.2% carboxymethyl cellulose (CMC) + 0.4% Tween-80 in saline) or increasing doses of either balaglitazone (0.1; 0.3; 1.0; 3.0; 10.0 mg/kg/day) or rosiglitazone (0.2; 0.6; 2.0; 6.0 mg/kg/day). After 7 days of treatment, plasma samples obtained in the morning (between 8:00 and 10:00 AM) are analyzed for glucose and insulin. After 9 days of treatment, animals are exposed to an oral glucose tolerance test (OGTT; 3.0 g/kg). The resulting area under the curve is calculated for each of the doses [1].
AliasNN-2344, NN2344, NN 2344, DRF-2593, DRF2593, DRF 2593
Chemical Properties
Molecular Weight395.43
FormulaC20H17N3O4S
Cas No.199113-98-9
SmilesCn1c(COc2ccc(CC3SC(=O)NC3=O)cc2)nc2ccccc2c1=O
Relative Density.1.45 g/cm3 (Predicted)
Storage & Solubility Information
Storagestore at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.
Solubility Information
DMSO: 80 mg/mL (202.31 mM), Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM2.5289 mL12.6445 mL25.2889 mL126.4446 mL
5 mM0.5058 mL2.5289 mL5.0578 mL25.2889 mL
10 mM0.2529 mL1.2644 mL2.5289 mL12.6445 mL
20 mM0.1264 mL0.6322 mL1.2644 mL6.3222 mL
50 mM0.0506 mL0.2529 mL0.5058 mL2.5289 mL
100 mM0.0253 mL0.1264 mL0.2529 mL1.2644 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
TargetMol | Animal experimentsFor example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . TargetMol | Animal experiments A total of 10 animals were administered, and the formula you used is 5% TargetMol | reagent DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。
Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSOTargetMol | reagent (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
Preparation method for in vivo formula: Take 50 μL DMSOTargetMol | reagent main solution, add 300 μLPEG300TargetMol | reagent mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2OTargetMol | reagent mix well and clarify
For Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
%Tween 80
%ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Balaglitazone | purchase Balaglitazone | Balaglitazone cost | order Balaglitazone | Balaglitazone chemical structure | Balaglitazone in vivo | Balaglitazone in vitro | Balaglitazone formula | Balaglitazone molecular weight